.webp)
Chemify have raised over £37 million in Series B funding to accelerate their mission of becoming the global leader in digital chemistry, molecular design and manufacturing. The oversubscribed round was co-led by Wing Venture Capital and Insight Partners, with participation from a syndicate of world-class investors including 8VC and existing backers Triatomic Capital, Blueyard, Rockspring and Eos.
Earlier this year, Chemify launched its first Chemifarm, a fully automated chemistry facility built to be the world’s most advanced laboratory for molecular design and synthesis. At its core, the Chemifarm integrates Chemify’s Chemputation platform, an extensible programming language, advanced robotics, and the world’s largest curated library of validated reactions. The platform opens new frontiers in the rapid, data-driven creation of molecules once deemed inaccessible.
The new Series B financing allows Chemify to expand this blueprint globally, building a network of digital chemistry hubs and delivering on-demand molecule design and manufacturing to pharmaceutical, biotech and materials-science partners everywhere. Chemify plans to open a Silicon Valley facility led by Chief Technical Officer Mike Bell.
This growth will enhance Chemify’s ability to deliver on-demand molecular design, optimisation and synthesis, dramatically compressing the timeline from concept to compound. The company’s goal is to lead the discovery of life-changing medicines and next-generation materials while establishing a new global standard for how small molecules are developed and manufactured.
Founded in 2022 as a spin-out from the University of Glasgow, Chemify is reinventing chemistry on a digital foundation, uniting automation, AI and data to accelerate the discovery of new medicines and advanced materials while shaping a scalable, global platform for molecular innovation.
